Improving first-line therapy of advanced ovarian cancer - the AGO Ovarian Cancer Study Group perspective
- 1 November 2003
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 13 (s2) , 169-171
- https://doi.org/10.1111/j.1525-1438.2003.t01-2-13352.x
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian CancerJNCI Journal of the National Cancer Institute, 2003
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- First-Line Chemotherapy With Epirubicin, Paclitaxel, and Carboplatin for Advanced Ovarian Cancer: A Phase I/II Study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study GroupJournal of Clinical Oncology, 1999
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996